Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Acuamark Diagnostics Announces Addition Of David C. Weavil To Its Board Of Directors

Acuamark Diagnostics Inc.
Posted on: 20 Oct 16

Acuamark Diagnostics, Inc., a biotechnology company that focuses on developing accurate and cost-effective blood-based screening tests for the early detection of cancer, today announced the addition of David C. Weavil to its Board of Directors.

Mr. David C. Weavil is a seasoned industry executive with over thirty years of experience in the diagnostics industry, and has a track record of successfully running and growing both public and private laboratory companies.

Mr. Weavil states: “I am very excited to join the Board of Directors of Acuamark Diagnostics. This extraordinary team is well on its way toward development of game changing early detection technology. I am humbled by this invitation and inspired by their passion, and I am anxious to help this talented and committed group of professionals achieve their vision of providing value-based blood testing for early detection of cancer.”

Previously, Mr. Weavil was CEO and President of Solstas Lab Partners Inc. which he founded, grew to over $400M in revenue and sold to Quest Diagnostics. Prior to that, David was CEO of Specialty Laboratories, currently owned by Quest. Earlier, as Chairman and CEO of California based Unilab Corporation, Mr. Weavil grew the company's revenues to over $350M, fueling shareholder value by over 14 times in a span of 3 years. Earlier, he helped build Biomedical Reference Labs from a small family-owned business into Roche Biomedical Labs, which then merged with National Health Labs to form LabCorp, one of the nation’s preeminent laboratory companies.

Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. (formerly iCareDx, Inc.) comments: "David is incredibly accomplished in the diagnostics industry, and will be a key contributor to Acuamark Diagnostics’ strategy and growth. We are excited to welcome David to the team, and we are honored that he has decided to join our efforts in blood-based early detection of cancer.”

Mr. Michael Gargano, Chairman of the Board of Acuamark Diagnostics, further adds: “I would like to welcome Mr. Weavil to the Board Of Directors of Acuamark Diagnostics. David has unparalleled management experience in the lab industry. His insights will be invaluable as we continue to execute our growth plans.”

About Acuamark Diagnostics Inc.

Acuamark Diagnostics is a biotechnology company focused on developing screening tests for blood-based early detection of cancer. Acuamark Diagnostics' technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.

For more information, please visit www.acuamarkdx.com, or contact us at info@acuamarkdx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020005350/en/

Business Wire
www.businesswire.com

Last updated on: 20/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.